| COMPANY |
Novo Nordisk A/S |
| COURT |
United States District Court for the District of New Jersey |
| CASE NUMBER |
3:25-cv-00713 |
| JUDGE |
The Hon. Robert Andrew Kirsch |
| CLASS PERIOD |
November 2, 2022, through December 19, 2024 |
| SECURITY TYPE |
Securities |
LEAD PLAINTIFF DEADLINE IS MARCH 25, 2025.
If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.
Case Background:
A class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Novo Nordisk A/S (“Novo”) (NYSE: NVO) securities between November 2, 2022, and December 19, 2024, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants provided overwhelmingly positive statements to investors concerning the details of, and expectations for, Novo’s phase 3 CagriSema study on obesity, named “REDEFINE-1.” Defendants’ statements failed to disclose or otherwise misled investors as to the nature of the dosages provided to patients in the REDEFINE-1 study. Defendants’ statements further included, among other things, significant confidence in Novo’s expectations for the study, in particular a minimum expected 25% average weight loss for obesity patients treated with CagriSema in the REDEFINE-1 study. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo’s REDEFINE-1 trial protocol; notably, that it was a “flexible protocol” which gave patients the ability “to modify their dosing throughout the trial.” As a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What is a Lead Plaintiff?
A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.